共 420 条
[1]
Larkin J(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34
[2]
Chiarion-Sileni V(2016)Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer N Engl J Med 375 1823-1833
[3]
Gonzalez R(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[4]
Grob JJ(2018)Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors Nat Rev Drug Discov 17 854-855
[5]
Cowey CL(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
[6]
Lao CD(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168
[7]
Schadendorf D(2017)Neurological adverse events associated with immune checkpoint inhibitors: review of the literature Eur J Cancer 73 1-8
[8]
Dummer R(2017)Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors Eur J Cancer 82 128-136
[9]
Smylie M(2017)Neurological toxicities associated with immune-checkpoint inhibitors Curr Opin Neurol 30 659-668
[10]
Rutkowski P(2018)Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis JAMA Oncol 4 173-182